Fig. 5: The pan-RAR antagonist AGN193109 decreases LSCe abundance and quiescence in an Evi1-dependent manner.

BM cells from terminally ill recipients of MA9-transduced LSK cells or CMPs, or of shRNA transduced LCLSK_MA9 were treated with 1 µM AGN193109 or solvent for 3 days. n = 3; *p < 0.05; **p < 0.01; ns, not significant; ANOVA followed by Bonferroni's post-hoc test. a Myeloid differentiation. b Proportions of LSCe among LCs. c Proportions of quiescent LSCe (LSCe in G0).